NEW YORK (GenomeWeb News) — Cepheid and Instrumentation Laboratory intend to develop and distribute diagnostics for hemostasis applications, Cepheid said today.  
Under the agreement, Cepheid will develop tests to be used on its GeneXpert technology, while IL will market them as part of its panel of hemostasis diagnostic assays.
Cepheid said it first plans to develop the Xpert HemosIL tests to detect Factor II and Factor V mutations, which are genetic variations associated with thrombosis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.